We are live on
!
Find out more
EU
Emory University Portfolio holdings
AUM
$160M
1-Year Est. Return
8.57%
This Fund
S&P 500
This Quarter
Est. Return
+15.98%
1 Year Est. Return
+8.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$142M
AUM Growth
+$15.4M
(+12%)
Cap. Flow
+$1.25M
Cap. Flow
% of AUM
0.88%
Top 10 Holdings %
Top 10 Hldgs %
49.55%
Holding
52
New
6
Increased
14
Reduced
22
Closed
7
Avg Time Held
5.9
quarters
Top 10 Avg Time Held
1.7
quarters
Top 20 Avg Time Held
2.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Solid Biosciences
SLDB
|
+$3.84M |
| 2 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$2.35M |
| 3 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$2.3M |
| 4 |
argenx
ARGX
|
+$2.21M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$2.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$2.33M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$1.98M |
| 3 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$1.84M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$1.76M |
| 5 |
Armstrong World Industries
AWI
|
+$1.66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.2% |
| 2 | Financials | 31.36% |
| 3 | Consumer Discretionary | 8.42% |
| 4 | Industrials | 2.47% |
| 5 | Technology | 1.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Berkshire Hathaway Class A
BRK.A
$1.11T
| $35.2M | 24.77% |
117
| – | – |
2016 Q4
9 quarters
|
|
2
JD.com
JD
$36.6B
| $12M | 8.42% |
397,528
-50
| -0% | -$1.27K |
2017 Q4
5 quarters
|
|
3
Ascendis Pharma A/S
ASND
$15.1B
| $3.82M | 2.69% |
32,477
-6,740
| -17% | -$590K |
2016 Q4
9 quarters
|
|
|
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
| $2.84M | 2% |
208,854
-9,020
| -4% | -$110K |
2017 Q2
7 quarters
|
|
|
AMRN
5
Amarin Corp
AMRN
$254M
| $2.8M | 1.97% |
6,753
+283
| +4% | +$102K |
2018 Q4
1 quarter
|
|
|
ORTX
6
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $2.8M | 1.97% |
+15,640
| New | +$2.35M |
2019 Q1
0 quarters
|
|
|
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
| $2.79M | 1.96% |
50,758
-7,064
| -12% | -$336K |
2016 Q4
9 quarters
|
|
8
Acadia Pharmaceuticals
ACAD
$3.41B
| $2.75M | 1.94% |
102,586
-20,029
| -16% | -$468K |
2015 Q1
16 quarters
|
|
|
9
Solid Biosciences
SLDB
$737M
| $2.75M | 1.93% |
19,926
+15,345
| +335% | +$3.84M |
2018 Q3
2 quarters
|
|
10
InflaRx
IFRX
$236M
| $2.72M | 1.91% |
71,884
-9,552
| -12% | -$356K |
2018 Q1
4 quarters
|
|
|
MYOV
11
DELISTED
Myovant Sciences Ltd.
MYOV
| $2.67M | 1.88% |
111,925
-12,226
| -10% | -$250K |
2017 Q2
7 quarters
|
|
|
RARX
12
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $2.67M | 1.87% |
118,959
-30,149
| -20% | -$648K |
2018 Q4
1 quarter
|
|
13
Travere Therapeutics
TVTX
$4.91B
| $2.5M | 1.76% |
110,627
+17,687
| +19% | +$391K |
2018 Q3
2 quarters
|
|
14
Neurocrine Biosciences
NBIX
$14.5B
| $2.49M | 1.75% |
28,287
+2,998
| +12% | +$251K |
2017 Q2
7 quarters
|
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals
ALXN
| $2.49M | 1.75% |
18,429
-1,238
| -6% | -$154K |
2015 Q2
15 quarters
|
|
16
Wave Life Sciences
WVE
$682M
| $2.46M | 1.73% |
63,434
+5,207
| +9% | +$211K |
2016 Q4
9 quarters
|
|
17
Incyte
INCY
$22.9B
| $2.45M | 1.72% |
28,518
-7,153
| -20% | -$582K |
2015 Q1
16 quarters
|
|
|
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.44M | 1.72% |
33,368
-8,171
| -20% | -$581K |
2015 Q1
16 quarters
|
|
|
THOR
19
DELISTED
Synthorx, Inc. Common Stock
THOR
| $2.44M | 1.71% |
+119,735
| New | +$2.06M |
2019 Q1
0 quarters
|
|
|
GBT
20
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $2.42M | 1.7% |
45,771
-16,872
| -27% | -$829K |
2017 Q2
7 quarters
|
|
|
ONC
21
BeOne Medicines Ltd
ONC
$40.1B
| $2.38M | 1.67% |
18,039
-129
| -0.7% | -$17.4K |
2017 Q1
8 quarters
|
|
|
22
argenx
ARGX
$51.9B
| $2.35M | 1.65% |
+18,819
| New | +$2.21M |
2019 Q1
0 quarters
|
|
|
ATNX
23
DELISTED
Athenex, Inc. Common Stock
ATNX
| $2.31M | 1.63% |
+9,435
| New | +$2.3M |
2019 Q1
0 quarters
|
|
24
BioMarin Pharmaceuticals
BMRN
$10.6B
| $2.25M | 1.58% |
25,376
+1,074
| +4% | +$99.5K |
2015 Q1
16 quarters
|
|
|
CRNX
25
DELISTED
Crinetics Pharmaceuticals
CRNX
| $2.21M | 1.55% |
97,035
+11,091
| +13% | +$273K |
2018 Q4
1 quarter
|
|
Similar funds
WH
CPW
NWS
SGM
CI
SA
SH
HA
Emory University's Q1 2019 Portfolio in Review
As of Q1 2019, Emory University held 52 positions worth $142M, up 12% from $127M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Emory University's Q1 2019 filing shows 6 new, 14 increased, 22 reduced and 7 closed positions. Its largest new stake was Orchard Therapeutics plc American Depositary Shares: 15,640 shares worth $2.8M. The largest sale was Alnylam Pharmaceuticals, an estimated $2.33M.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 53% a quarter earlier, followed by Financials and Consumer Discretionary.
- Emory University's largest Q1 2019 buy was Orchard Therapeutics plc American Depositary Shares: 15,640 shares worth $2.8M.
- Emory University added most to Solid Biosciences in Q1 2019, an estimated $3.84M increase.
- Emory University's biggest Q1 2019 reduction was Global Blood Therapeutics, Inc., cutting an estimated $829K.
- Emory University fully exited Alnylam Pharmaceuticals in Q1 2019, selling an estimated $2.33M.
- Emory University's ten largest holdings make up 50% of its $142M portfolio in Q1 2019.
- Emory University opened 6 new positions and closed 7 in Q1 2019.
- Emory University's portfolio value rose 12% quarter-over-quarter to $142M.
Based on Emory University's 13F filing for Q1 2019, filed 9 May 2019.